Cicatricial pemphigoid (mucous membrane pemphigoid): Current and emerging therapeutic approaches

American Journal of Clinical Dermatology

Volumn 6, Issue 2, 2005, Pages 93-103

  Sacher, Christopher ^a   Hunzelmann, Nicolas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETAMETHASONE; CALCINEURIN INHIBITOR; CLOBETASOL; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; DAPSONE; DERMATOLOGICAL AGENT; DEXAMETHASONE; FLUOCINONIDE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MEPREDNISONE; METHOTREXATE; MITOMYCIN C; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISONE; SULFAPYRIDINE; SULFONE DERIVATIVE; TACROLIMUS; TETRACYCLINE; TETRACYCLINE DERIVATIVE; THALIDOMIDE;

ABDOMINAL CRAMP; ALLERGY; ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; BULLOUS SKIN DISEASE; CLINICAL TRIAL; CONVULSION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EPIDERMOLYSIS BULLOSA ACQUISITA; ERYTHEMA MULTIFORME; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION RISK; INSOMNIA; LICHEN PLANUS; LYMPHOCYTOPENIA; LYMPHOMA; MUCOUS MEMBRANE PEMPHIGOID; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; PARANEOPLASTIC SYNDROME; PEMPHIGOID; PEMPHIGUS VULGARIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TOPICAL TREATMENT; TREMOR; URINARY HESITANCY; VOMITING;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CALCINEURIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MITOMYCIN; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PLASMAPHERESIS; TETRACYCLINES;

EID: 17244379714     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200506020-00004     Document Type: Review

References (110)

1. Chan LS, Ahmed AR, Anhalt GJ, et al. The First International Consensus on Mucous Membrane Pemphigoid. Arch Dermatol 2002 Mar; 138: 370-9
2. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000 Oct; 43: 571-91
3. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen BP 180. J Clin Invest 1993 Nov; 92: 2480-8
4. Lazarova Z, Yee C, Darling T, et al. Passive transfer of laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 1996; 98: 1509-18
5. Budinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T-cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998; 102: 2082-9
6. Axt M, Wever S, Baier G, et al. Cicatricial pemphigoid: a therapeutic problem. Hautarzt 1995 Sep; 46: 620-7
7. Ahmed AR, Kurgis BS, Rogers III RS. Cicatricial pemphigoid. J Am Acad Dermatol 1991 Jun; 24: 987-1001
8. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84: 527-663
9. Lozada-Nur F, Miranda C, Maliksi R. Double-blind clinical trial of 0.05% clobetasol propionate (corrected from proprionate) ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 1994 Jun; 77: 598-604
10. Gonzalez-Moles MA, Morales P, Rodriguez-Archilla A, et al. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002 Mar; 93: 264-70
11. Lee MS, Wakefield PE, Konzelman JL, et al. Oral insertable prosthetic device as an aid in treating oral ulcers. Arch Dermatol 1991 Apr; 127: 479-80
12. Joly P, Roujeau JC, Benichou J, et al. Bullous Diseases French Study Group. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002 Jan 31; 346: 321-7
13. Phillips B, Ball C, Sackett D, et al. Centre for Evidence Based Medicine, Oxford UK. Levels of evidence and grades of recommendations [online]. Available from URL http://www.cebm.net/levels_of_evidence.asp [Accessed 2005 Jan 27]
14. Humbert P, Treffel P, Chapuis JF, et al. The tetracyclines in dermatology. J Am Acad Dermatol 1991 Oct; 25: 691-7
15. Bauco van der Wal V, Jonkman MF. Topical tetracycline in Cicatricial pemphigoid. J Am Acad Dermatol 1997 Mar; 36: 492-3
16. Jampel HD. Effect of brief exposure to mitomycin C on viability and proliferation of cultured human Tenon's capsule fibroblasts. Ophthalmology 1992 Sep; 99: 1471-6
17. Secchi AG, Tognon MS. Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices. Am J Ophthalmol 1996 Nov; 122: 728-30
18. Donnenfeld ED, Perry HD, Wallerstein A, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Ophthalmology 1999 Jan; 106: 72-8
19. Rivas Jara L, Celis Sanchez J. Mitomycin C treatment for ocular cicatricial pemphigoid. Arch Soc Esp Oftalmol 2003 Feb; 78: 71-2
20. Celis Sanchez J, Lopez Ferrando N, Garcia Largacha M, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Arch Soc Esp Oftalmol 2002 Sep; 77: 385-9
21. Eisen D, Ellis CN, Voorhees JJ. Topical cyclosporine for oral bullous disorders. J Am Acad Dermatol 1990 Nov; 23: 936-7
22. Azana JM, de Misa RF, Boixeda JP, et al. Topical cyclosporine for cicatricial pemphigoid. J Am Acad Dermatol 1993 Jan; 28: 134-5
23. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993 Sep; 12: 413-9
24. Reinhard T, Reis A, Mayweg S, et al. Topical FK506 in inflammatory corneal and conjunctival diseases: a pilot study. Klin Monatsbl Augenheilkd 2002 Mar; 219: 125-31
25. Eggleston DJ, Nally FF. Treatment of aphthous ulceration with topical azathioprine: a double blind trial. Br J Oral Surg 1972 Mar; 9: 233-6
26. Suchko VI, Mashchenko IS. Local use of an azathioprine suspension in a dimexide solution in the combined treatment of periodontosis. Stomatologiia (Mosk) 1981 May-Jun; 60: 28-30
27. Epstein JB, Gorsky M, Epstein MS, et al. Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions: a series of cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001 Jan; 91: 56-61
28. Gillies M, Francis I, McCluskey P, et al. Local interferon alfa-2b for ocular cicatricial pemphigoid [letter]. Br J Ophthalmol 1996 Oct; 80: 927
29. Carrozzo M, Carbone M, Broccoletti R, et al. Therapeutic management of mucous membrane pemphigoid: report of 11 cases. Minerva Stomatol 1997 Oct; 46: 553-9
30. Carbone M, Carrozzo M, Castellano S, et al. Systemic corticosteroid therapy of oral vesiculoerosive diseases (OVED): an open trial. Minerva Stomatol 1998 Oct; 47: 479-87
31. Appelhans M, Bonsmann G, Orge C, et al. Dexamethasone-cyclophosphamide pulse therapy in bullous autoimmune dermatoses. Hautarzt 1993 Mar; 44: 143-7
32. DeHoratius DM, Sperber BR, Werth VP. Glucocorticoids in the treatment of bullous diseases. Dermatol Ther 2002; 15: 298-310
33. Mimouni D, Nousari HC. Inhibitors of purine and pyrimidine synthesis: mycophenolate, azathioprine, and leflunomide. Dermatol Ther 2002; 15: 311-6
34. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39
35. Dave VK, Vickers CF. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol 1974 Feb; 90: 183-6
36. Braun-Falco O. Wolff HH, Ponce E. Disseminated cicatricial pemphigoid. Hautarzt 1981 May; 32: 233-9
37. Pawlofsky C, Simon M, Fartasch M, et al. Disseminated cicatricial pemphigoid. Dermatologica 1985; 171: 259-63
38. Bialasiewicz AA, Forster W, Radig H, et al. Syngeneic transplantation of nasal mucosa and azathioprine medication for therapy of cicatricial ocular mucous membrane pemphigoid: study of 9 patients with 11 eyes. Ophthalmologe 1994 Apr; 91: 244-50
39. Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991 May; 10: 185-95
40. Kitchin JE, Pomeranz MK, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997 Sep; 37: 445-9
41. Grundmann-Kollmann M, Kaskel P, Leiter U, et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999 Jun; 135: 724-5
42. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999 Jun; 40: 957-60
43. Bredlich RO, Grundmann-Kollmann M, Behrens S, et al. Mycophenolate mofetil monotherapy for pemphigus vulgaris [letter]. Br J Dermatol 1999 Nov; 141: 934
44. Nousari HC, Goyal S, Anhalt GJ. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch Dermatol 1999 Nov; 135: 1420-1
45. Nousari HC, Anhalt GJ. The role of mycophenolate mofetil in the management of pemphigus. Arch Dermatol 1999 Jul; 135: 853-4
46. Nousari HC, Sragovich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999 Feb; 40: 265-8
47. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999 Jan; 135: 54-6
48. Megahed M, Schmiedeberg S, Becker J, et al. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2001 Aug; 45: 256-9
49. Reis A, Reinhard T, Sundmacher R, et al. Mycophenolate mofetil in ocular immunological disorders: a survey of the literature with 3 case reports. Klin Monatsbl Augenheilkd 1998 Nov; 213: 257-61
50. Zurdel J, Aboalchamat B, Zierhut M, et al. Early clinical results with mycophenolate mofetil in immunosuppressive therapy of ocular pemphigoid. Klin Monatsbl Augenheilkd 2001 Apr; 218: 222-8
51. Germanas J, Pandya AG. Alkylating agents. Dermatol Ther 2002; 15: 317-24
52. Pandya AG, Warren KJ, Bergstresser PR. Cicatricial pemphigoid successfully treated with pulse intravenous cyclophosphamide. Arch Dermatol 1997 Feb; 133: 245-7
53. Musette P, Pascal F, Hoang-Xuan T, et al. Treatment of cicatricial pemphigoid with pulse intravenous cyclophosphamide. Arch Dermatol 2001 Jan; 137: 101-2
54. Brody HJ, Pirozzi DJ. Benign mucous membrane pemphigoid: response to therapy with cyclophosphamide. Arch Dermatol 1977 Nov; 113: 1598-9
55. Tharp MD. Calcineurin Inhibitors. Dermatol Ther 2002; 15: 325-32
56. Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000 Jul; 136: 868-72
57. Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol 1992; 82: 223-9
58. Williams DY, Oziemski M, Varigos G. Cyclosporine therapy of life-threatening cicatricial pemphigoid affecting the respiratory tract. Int J Dermatol 1995 Sep; 34: 639-41
59. Letko E, Ahmed AR, Foster CS. Treatment of ocular cicatricial pemphigoid with tacrolimus (FK 506). Graefes Arch Clin Exp Ophthalmol 2001 Jul; 239: 441-4
60. Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide: a novel immunomodulatory agent. Arch Dermatol 2000 Oct; 136: 1204-5
61. Boedeker CC, Termeer CC, Staats R, et al. Cicatricial pemphigoid in the upper aerodigestive tract: diagnosis and management in severe laryngeal stenosis. Ann Otol Rhinol Laryngol 2003 Mar; 112: 271-5
62. Miserocchi E, Baltatzis S, Roque MR, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology 2002 Jan; 109: 111-8
63. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999 Nov; 106: 2136-43
64. Miserocchi E, Waheed NK, Baltatzis S, et al. Chronic cicatrizing conjunctivitis in a patient with ocular cicatricial pemphigoid and fatal Wegener granulomatosis. Am J Ophthalmol 2001 Dec; 132: 923-4
65. Rogers III RS, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982 Feb; 6: 215-23
66. Rogers III RS, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988 Sep; 7: 201-5
67. Ciarrocca KN, Greenberg MS. A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Aug; 88: 159-63
68. Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997 Dec; 62: 827-36
69. Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993 Nov; 129: 507-13
70. Prussick R, Shear NH. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996 Aug; 35: 346-9
71. Elder MJ, Leonard J, Dart JK. Sulphapyridine: a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996 Jun; 80: 549-52
72. Doan S, Lerouic JF, Robin H, et al. Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmology 2001 Sep; 108: 1565-8
73. Le Rouic JF, Robin H, Doan S. et al. Treatment of ocular cicatricial pemphigoid with sulfasalazine. J Fr Ophtalmol 1999 May; 22: 423-5
74. Thornhill M, Pemberton M, Buchanan J, et al. An open clinical trial of sulphamethoxypyridazine in the treatment of mucous membrane pemphigoid. Br J Dermatol 2000 Jul; 143: 117-26
75. McFadden JP, Leonard JN, Powles AV, et al. Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 1989 Dec; 121: 759-62
76. Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide: a preliminary report. Arch Dermatol 1986 Jun; 122: 670-4
77. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994 Jun; 130: 753-8
78. Mallon E, Wojnarowska F. Cicatricial pemphigoid presenting with unusual palmar involvement, successfully treated with a combination of nicotinamide and tetracycline. Clin Exp Dermatol 1994 Nov; 19: 526-30
79. Poskitt L, Wojnarowska F. Treatment of cicatricial pemphigoid with tetracycline and nicotinamide. Clin Exp Dermatol 1995 May; 20: 258-9
80. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol 1998 Nov; 23: 254-7
81. Dragan L, Eng AM, Lam S, et al. Tetracycline and niacinamide: treatment alternatives in ocular cicatricial pemphigoid. Cutis 1999 Mar; 63: 181-3
82. Kreyden OP, Borradori L, Trueb RM, et al. Successful therapy with tetracycline and nicotinamide in cicatricial pemphigoid. Hautarzt 2001 Mar; 52: 247-50
83. Sakamoto K, Mori K, Hashimoto T, et al. Antiepiligrin cicatricial pemphigoid of the larynx successfully treated with a combination of tetracycline and niacinamide. Arch Otolaryngol Head Neck Surg 2002 Dec; 128: 1420-3
84. Calderon P, Anzilotti M, Phelps R. Thalidomide in dermatology: new indications for an old drug. Int J Dermatol 1997 Dec; 36: 881-7
85. Hendler SS, McCarty MF. Thalidomide for autoimmune disease. Med Hypotheses 1983 Apr; 10: 437-43
86. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994 Dec; 53: 828-32
87. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984 Nov; 23: 598-602
88. Duong DJ, Moxley III RT, Kellman RM, et al. Thalidomide therapy for cicatricial pemphigoid. J Am Acad Dermatol 2002 Aug; 47: S193-5
89. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981 Jun 6; I: 1228-31
90. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001 Nov; 45: 679-90
91. Jolles S. High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Exp Immunol 2002 Sep; 129: 385-9
92. Sami N, Qureshi A, Ruocco E, et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002 Sep; 138: 1158-62
93. Meurer M, Messer G. Plasmapheresis and intravenous immunoglobulin. Dermatol Ther 2002; 15: 333-9
94. Urcelay ML, McQueen A, Douglas WS. Cicatricial pemphigoid treated with intravenous immunoglobulin. Br J Dermatol 1997 Sep; 137: 477-8
95. Letko E, Bhol K, Foster SC, et al. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid: a correlation with disease activity: a preliminary study. Curr Eye Res 2000 Aug; 21: 646-54
96. Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 2001 Sep; 137: 1181-9
97. Sami N, Bhol KC, Ahmed AR. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002 Jan; 102: 59-67
98. Sami N, Bhol KC, Ahmed AR. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy: long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin. Clin Exp Immunol 2002 Sep; 129: 533-40
99. Leverkus M, Georgi M, Nie Z, et al. Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin. J Am Acad Dermatol 2002 Jan; 46: 116-22
100. Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1978 Feb; 98: 243
101. Meurer M, Braun-Falco O. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1979 Feb; 100: 231-2
102. Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000 Dec; 43: 1058-64
103. Guillaume JC, Roujeau JC, Morel P, et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988 Nov; 124: 1659-63
104. Bohn J, Jonsson S, Holst R. Successful treatment of recalcitrant cicatricial pemphigoid with a combination of plasma exchange and cyclophosphamide. Br J Dermatol 1999 Sep; 141: 536-40
105. Hashimoto Y, Suga Y, Yoshiike T, et al. A case of antiepiligrin cicatricial pemphigoid successfully treated by plasmapheresis. Dermatology 2001; 201: 58-60
106. Lee SJ, Li Z, Sherman B, et al. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1993 Dec; 34: 3522-5
107. Sacher C, Rubbert A, Konig C, et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002 Jan; 46: 113-5
108. Leyendeckers H, Tasanen K, Bruckner-Tuderman L, et al. Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies. J Invest Dermatol 2003 Mar; 120: 372-8
109. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003 Mar; 148: 602-3
110. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002 Nov; 47: 785-8